Esmeron

  • Name:

    Esmeron

  • Company:
    info
  • Active Ingredients:

    Rocuronium Bromide

  • Legal Category:

    Product subject to medical prescription which may not be renewed (A)

Patient Information Leaflet Patient Information Leaflet last updated on medicines.ie: 28/05/20

files-icon(Click to Download)
Summary of Product Characteristics last updated on medicines.ie: 28/5/2020

Click on this link to Download PDF directly

MSD Ireland (Human Health) Limited

02852_MSD_Logo_W-Anthem_Horizontal_Teal&Grey_RGB_1589289143

Company Products

Medicine NameActive Ingredients
Medicine Name Adempas Film Coated Tablets Active Ingredients Riociguat
Medicine Name Arcoxia 30 60 90 120 film-coated tablets Active Ingredients Etoricoxib
Medicine Name Atozet 10mg/10mg, 10mg/20mg, 10mg/40mg and 10mg/80mg film-coated tablets Active Ingredients Atorvastatin calcium trihydrate, ezetimibe
Medicine Name Bridion Active Ingredients Sugammadex sodium
Medicine Name Cancidas 50mg Powder for concentrate for solution for infusion Active Ingredients caspofungin acetate
Medicine Name Cancidas 70mg Powder for concentrate for solution for infusion Active Ingredients caspofungin acetate
Medicine Name Cerazette 75 microgram film-coated tablet Active Ingredients Desogestrel
Medicine Name Cozaar 12.5mg, 50mg & 100mg Film-coated Tablets Active Ingredients Losartan potassium
Medicine Name Cozaar COMP 50 mg/12.5 mg, 100 mg/12.5 mg, 100 mg/25 mg film-coated tablets Active Ingredients Hydrochlorothiazide, Losartan potassium
Medicine Name Cubicin 350mg Powder for Solution for injection or infusion Active Ingredients Daptomycin
Medicine Name Cubicin 500mg powder for solution for injection or infusion Active Ingredients Daptomycin
Medicine Name Delstrigo 100 mg/300 mg/245 mg film-coated tablets Active Ingredients Lamivudine, Tenofovir disoproxil fumarate, Doravirine
Medicine Name Diprosalic Scalp Application Active Ingredients Betamethasone dipropionate, Salicylic Acid
Medicine Name Elocon Cream Active Ingredients Mometasone Furoate
Medicine Name Elocon Ointment Active Ingredients Mometasone Furoate
Medicine Name EMEND 80mg, 125mg hard Capsules Active Ingredients Aprepitant
Medicine Name Esmeron Active Ingredients Rocuronium Bromide
Medicine Name EZETROL 10 mg Tablets Active Ingredients ezetimibe
Medicine Name FOSAMAX Once Weekly 70 mg Tablets Active Ingredients Alendronate Sodium Trihydrate
Medicine Name FOSAVANCE Active Ingredients Alendronate Sodium Trihydrate, Colecalciferol (Vitamin D3)
Medicine Name GARDASIL Active Ingredients human papillomavirus vaccine
Medicine Name Gardasil 9 suspension for injection in a pre-filled syringe Active Ingredients Human papillomavirus 9-valent vaccine
Medicine Name HALF SINEMET CR 25mg/100mg Prolonged-Release Tablets Active Ingredients Carbidopa, Levodopa
Medicine Name HBVAXPRO 10mcg Active Ingredients Hepatitis B vaccine (rDNA)
Medicine Name HBVAXPRO 40mcg Active Ingredients Hepatitis B vaccine (rDNA)
1 - 0 of 74 items.Total: Infinity pages

When a pharmaceutical company changes any document, a new version is published on medicines.ie. For each version, we show the dates it was published on medicines.ie and the reasons for change.

Updated on 28 May 2020 SmPC

Reasons for updating

  • Change to section 4.8 - Undesirable effects
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Kounis syndrome added as an undesirable effectKounis syndrome added as an undesirable effect

 

Updated on 28 May 2020 PIL

Reasons for updating

  • Change to section 4 - possible side effects
  • Change to section 6 - date of revision

Updated on 24 July 2018 PIL

Reasons for updating

  • Change to section 6 - marketing authorisation holder
  • Change to section 6 - date of revision

Updated on 24 July 2018 SmPC

Reasons for updating

  • Change to section 7 - Marketing authorisation holder
  • Change to section 8 - Marketing authorisation number(s)
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Change to the PA holder and number

Updated on 25 January 2018 SmPC

Reasons for updating

  • New SmPC for new product

Legal category: Product subject to medical prescription which may not be renewed (A)

Updated on 25 January 2018 SmPC

Reasons for updating

  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.6 - Pregnancy and lactation
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

4.4 Observed rare cases of hyperthermia and  4.6 Breastfeeding  

Updated on 24 January 2018 PIL

Reasons for updating

  • New PIL for new product

Updated on 24 January 2018 PIL

Reasons for updating

  • Change to section 6 - date of revision
  • Change to section 2 - pregnancy, breast feeding and fertility

Updated on 5 July 2016 SmPC

Reasons for updating

  • Change to section 4.9 - Overdose
  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

To update information on the use of sugammadex to reverse neuromuscular blockade.

Updated on 22 December 2015 SmPC

Reasons for updating

  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

       Changes to sections: 2, Qualitative and Quantitative Composition, 4.4, special warnings and precautions for use,  section 10, date of revision of text

Updated on 22 December 2015 PIL

Reasons for updating

  • Change to warnings or special precautions for use
  • Change to further information section
  • Change to date of revision

Updated on 27 February 2015 PIL

Reasons for updating

  • Change to further information section
  • Change to date of revision

Updated on 7 October 2014 SmPC

Reasons for updating

  • Change to section 4.4 - Special warnings and precautions for use
  • Change to Section 4.8 – Undesirable effects - how to report a side effect
  • Change to section 10 - Date of revision of the text
  • Change to improve clarity and readability

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Changes to sections: 4.4, special warnings and precautions for use, 4.8 undesirable effects-how to report a side effect, section 10, date of revision of text and Change to improve clarity and readability

Updated on 6 October 2014 PIL

Reasons for updating

  • Addition of information on reporting a side effect.

Updated on 11 June 2013 PIL

Reasons for updating

  • Change to storage instructions
  • Change to dosage and administration

Updated on 22 May 2013 SmPC

Reasons for updating

  • Change to section 4.1 - Therapeutic indications
  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.8 - Undesirable effects
  • Change to section 4.9 - Overdose
  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 5.2 - Pharmacokinetic properties
  • Change to section 6.4 - Special precautions for storage

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Changes to sections: 4.1, 4.2, 4.4, 4.5, 4.8, 4.9, 5.1, 5.2, 6.4.

Updated on 3 June 2011 SmPC

Reasons for updating

  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.9 - Overdose
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

4.2       Posology and method of administration

 

Text added:

“(see section 4.5)”

 

Deleted text:

“There are no data to support dose recommendations for the facilitation of mechanical ventilation in pediatric and geriatric patients”

 

4.4       Special warnings and precautions for use

 

Text added:

“In the case of intubation difficulties resulting in a clinical need for immediate reversal of rocuronium induced neuromuscular block, the use of a reversal agent should be considered.”

4.5       Interaction with other medicinal products and other forms of interaction

 

Deleted text:

·        “Theophylline”

 

Deleted text:

“Animal studies do not indicate direct or indirect harmful effects with respect to pregnancy, embryonal/foetal development, parturition or postnatal development.”

 

4.9                Overdose

 

Deleted text:

“Upon start of spontaneous recovery”

 

Text added:

“In this situation there are two options for the reversal of neuromuscular block: (1) Sugammadex can be used for reversal of intense (profound) and deep block. The dose of Sugammadex to be administered depends on the level of neuromuscular block. The use of Sugammadex for the purposes of reversal of rocuronium-induced blockade is recommended for use only in the adult population. There are specific circumstances for which Sugammadex may be useful (refer to section 5.1 Reversal of neuromuscular block). (2) An acetylcholinesterase inhibitor (e.g. neostigmine, edrophonium, pyridostigmine) can be used once spontaneous recovery starts and should be administered in adequate doses.”

 

Addition of new subheading:

“Geriatric patients and patients with hepatic and biliary tract disease and/or renal failure”


Rewording of subheading “Reversal of muscle relaxation”

 

Deleted text:

“Administration of”

 

“antagonises the action of Esmeron”

 

Reworded to read:

“The action of rocuronium can be antagonised either by Sugammadex or by acetylcholinesterase inhibitors (neostigmine, pyridostigmine or edrophonium). Sugammadex can be given for routine reversal (at 1-2 post-tetanic counts to reappearance of T2) or immediate reversal (3 minutes after rocuronium bromide administration). Acetylcholinesterase inhibitors can be administered at reappearance of T2 or at the first signs of clinical recovery. The use of Sugammadex for the purposes of reversal of rocuronium-induced blockade is recommended for use only in the adult population.”

 

 

10: Date of (partial) revision of the text

Deleted text:

“November 2009”


Text added:
March 2011

Updated on 3 June 2011 PIL

Reasons for updating

  • Change to improve clarity and readability

Updated on 14 July 2008 PIL

Reasons for updating

  • Change to side-effects
  • Change to drug interactions
  • Change to information about pregnancy or lactation
  • Change to information about driving or using machinery
  • Change to date of revision
  • Change to dosage and administration
  • Change of contraindications
  • Changes to therapeutic indications

Updated on 14 July 2008 SmPC

Reasons for updating

  • Change to section 1 - Name of medicinal product
  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 3 - Pharmaceutical form
  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.3 - Contraindications
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.6 - Pregnancy and lactation
  • Change to section 4.7 - Effects on ability to drive and use machines
  • Change to section 4.8 - Undesirable effects
  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 5.2 - Pharmacokinetic properties
  • Change to section 6.2 - Incompatibilities
  • Change to section 6.3 - Shelf life
  • Change to section 6.4 - Special precautions for storage
  • Change to section 6.5 - Nature and contents of container
  • Change to section 9 - Date of renewal of authorisation
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Section 1 - update to trade name
Section 2 - more detail added to qualitative and quantitative composition
Section 3 - update to pharmacetical name
Section 4.2 - additional information included for surgical procedures and ICU procedures
Section 4.3 - rewording of text
Section 4.4 - revision of text and warnings and precautions updated
Section 4.5 - revisioin of interactions
Section 4.6 - update to pregnancy and lactation information
Section 4.7 - rewording of text
Section 4.8 - addition of table of undesirable effects
Section 5.1 - update to pharmacodynamic properties
Section 5.2 - update to pharmacokinetic properties
Section 6.2 - incompatabilities information updated
Section 6.3 - shelf life after opening updated
Section 6.4 - storage precautions updated
Section 6.5 - additional information added
Section 9 - rewording
Section 10 - date of revision of text updated

Updated on 3 January 2007 PIL

Reasons for updating

  • Change of active ingredient
  • Change to storage instructions
  • Change to date of revision
  • Improved electronic presentation

Updated on 8 August 2006 SmPC

Reasons for updating

  • Correction of spelling/typing errors

Legal category: Product subject to medical prescription which may not be renewed (A)

Updated on 15 February 2005 SmPC

Reasons for updating

  • New SPC for medicines.ie

Legal category: Product subject to medical prescription which may not be renewed (A)

Updated on 15 February 2005 PIL

Reasons for updating

  • New PIL for medicines.ie